Blueprint Medicines
BPMC
BPMC was delisted on the 17th of July, 2025.
305 hedge funds and large institutions have $7.15B invested in Blueprint Medicines in 2024 Q2 according to their latest regulatory filings, with 50 funds opening new positions, 115 increasing their positions, 100 reducing their positions, and 25 closing their positions.
167% more funds holding in top 10
Funds holding in top 10: 3 → 8 (+5)
110% more call options, than puts
Call options by funds: $295M | Put options by funds: $140M
100% more first-time investments, than exits
New positions opened: 50 | Existing positions closed: 25
15% more repeat investments, than reductions
Existing positions increased: 115 | Existing positions reduced: 100
14% more capital invested
Capital invested by funds: $6.25B → $7.15B (+$903M)
8% more funds holding
Funds holding: 283 → 305 (+22)
1.66% less ownership
Funds ownership: 107.6% → 105.94% (-1.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$54M |
| 2 |
1832 Asset Management
Toronto,
Ontario, Canada
|
+$50.3M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$22.9M |
| 4 |
Holocene Advisors
New York
|
+$22.8M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$22.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$94M |
| 2 |
Pictet Asset Management
Carouge,
Switzerland
|
-$73.8M |
| 3 |
Morgan Stanley
New York
|
-$63.8M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$37.8M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$33.6M |
BPMC Hedge Fund Activity: Q2 2024 in Review
305 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q2 2024, worth a combined $7.15B — up 14% from $6.25B a quarter earlier.
Buyers outnumbered sellers: 50 funds opened new BPMC positions and 25 closed out — a net gain of 25 holders — while 115 added to existing stakes and 100 trimmed.
The largest buyer was Millennium Management, adding an estimated $54M. The largest seller was Wellington Management Group, cutting an estimated $94M.
- 305 institutional investors held Blueprint Medicines (BPMC) as of Q2 2024, up from 283 in Q1 2024.
- Funds reported $7.15B of Blueprint Medicines stock for Q2 2024, up 14% quarter-over-quarter.
- 50 funds opened new Blueprint Medicines positions in Q2 2024 and 25 closed out, a net change of +25 holders.
- The largest Blueprint Medicines buyer in Q2 2024 was Millennium Management, an estimated $54M added.
- The largest Blueprint Medicines seller in Q2 2024 was Wellington Management Group, an estimated $94M sold.
Based on aggregated 13F filings for Q2 2024.